Beximco acquires Nuvista stake
Beximco Pharmaceuticals has acquired a majority 85.2% stake in fellow Bangladeshi firm Nuvista Pharma for £18.2 million (US$25.2 million). In early October last year, Beximco entered into a non-binding memorandum of understanding with the hormone and steroid drug specialist (Generics bulletin, 13 October 2017, page 3).
You may also be interested in...
Beximco has completed its acquisition of a majority stake in Sanofi Bangladesh to “expand its core capabilities and product offerings.” With its second major acquisition under its belt, Beximco said that it plans to continue its diversification and expansion.
Beximco has struck a deal worth nearly $50m to acquire a majority stake in Sanofi Bangladesh, allowing the firm to expand in its domestic market.
Shipping a fourth product to the US, as well as two launches in Canada, ensured exports accounted for more than a tenth of Bangladeshi producer Beximco’s half-year turnover.